{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:24:25Z","timestamp":1784309065610,"version":"3.55.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"41","license":[{"start":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T00:00:00Z","timestamp":1693008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T00:00:00Z","timestamp":1693008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100015390","name":"University of Franche Comt\u00e9","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100015390","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100015390","name":"University of Franche-Comt\u00e9","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100015390","id-type":"DOI","asserted-by":"crossref"}]},{"name":"CHU Besan\u00e7on"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2023,10,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Human cytomegalovirus (HCMV) infection has been implicated in epithelial ovarian cancer (OC). Polyploidy giant cancer cells (PGCCs) have been observed in high-grade serous ovarian carcinoma (HGSOC); they possess cancer stem cell-like characteristics and give rise to progeny cells expressing epithelial-mesenchymal transition (EMT) markers. EZH2 plays a potential oncogenic role, correlating with high proliferative index and tumor grade in OC. Herein, we present the experimental evidence for HCMV as a reprogramming vector that elicited human ovarian epithelial cells (OECs) transformation leading to the generation of \u201c<jats:italic>CMV-transformed Ovarian cells<\/jats:italic>\u201d (CTO). The infection with the two high-risk clinical strains, namely HCMV-DB and BL provoked a distinct cellular and molecular mechanisms in infected OECs. EZH2 upregulation and cellular proliferation were curtailed by using EZH2 inhibitors. The HGSOC biopsies were characterized by an elevated EZH2 expression, possessing a strong positive correlation between the aforementioned marker and HCMV. From HGSOC biopsies, we isolated three HCMV clinical strains that transformed OECs generating CTO cells which displayed proliferative potentials in addition to EZH2 upregulation and PGCCs generation; these features were reduced upon EZH2 inhibition. High-risk HCMV strains transformed OECs confirming an HCMV-induced epithelial ovarian cancer model and highlighting EZH2 tumorigenic properties. Our findings might be highly relevant in the pathophysiology of ovarian tumors thereby nominating new targeted therapeutics.<\/jats:p>","DOI":"10.1038\/s41388-023-02813-4","type":"journal-article","created":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T07:02:13Z","timestamp":1693033333000},"page":"3047-3061","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Polyploidy, EZH2 upregulation, and transformation in cytomegalovirus-infected human ovarian epithelial cells"],"prefix":"10.1038","volume":"42","author":[{"given":"Ranim","family":"El Baba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5375-0874","authenticated-orcid":false,"given":"Sandy","family":"Haidar Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Monnien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Racha","family":"Mansar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Bibeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7993-0221","authenticated-orcid":false,"given":"Georges","family":"Herbein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,26]]},"reference":[{"key":"2813_CR1","doi-asserted-by":"publisher","first-page":"351.","DOI":"10.3390\/biomedicines9040351","volume":"9","author":"M Cox","year":"2021","unstructured":"Cox M, Kartikasari AER, Gorry PR, Flanagan KL, Plebanski M. Potential Impact of Human Cytomegalovirus Infection on Immunity to Ovarian Tumours and Cancer Progression. Biomedicines. 2021;9:351. https:\/\/doi.org\/10.3390\/biomedicines9040351.","journal-title":"Biomedicines"},{"key":"2813_CR2","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/d41586-022-04169-3","volume":"612","author":"D Dangaj Laniti","year":"2022","unstructured":"Dangaj Laniti D, Coukos G. Genetics and anatomy sculpt immune-cell partners of ovarian cancer. Nature. 2022;612:634\u20136. https:\/\/doi.org\/10.1038\/d41586-022-04169-3.","journal-title":"Nature"},{"key":"2813_CR3","doi-asserted-by":"publisher","first-page":"175883592110398","DOI":"10.1177\/17588359211039899","volume":"13","author":"A Leary","year":"2021","unstructured":"Leary A, Tan D, Ledermann J. Immune checkpoint inhibitors in ovarian cancer: where do we stand?. Ther Adv Med Oncol. 2021;13:175883592110398. https:\/\/doi.org\/10.1177\/17588359211039899.","journal-title":"Ther Adv Med Oncol"},{"key":"2813_CR4","doi-asserted-by":"publisher","first-page":"1067.","DOI":"10.3390\/cancers15041067","volume":"15","author":"PJ Wysocki","year":"2023","unstructured":"Wysocki PJ, \u0141obacz M, Potocki P, Kwinta \u0141, Micha\u0142owska-Kaczmarczyk A, S\u0142owik A. et al. Metronomic Chemotherapy Based on Topotecan or Topotecan and Cyclophosphamide Combination (CyTo) in Advanced, Pretreated Ovarian Cancer. Cancers. 2023;15:1067. https:\/\/doi.org\/10.3390\/cancers15041067.","journal-title":"Cancers"},{"key":"2813_CR5","doi-asserted-by":"publisher","first-page":"10078.","DOI":"10.3390\/ijms231710078","volume":"23","author":"P-Q Lim","year":"2022","unstructured":"Lim P-Q, Han I-H, Seow K-M, Chen K-H. Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Overview of the Molecular and Cellular Mechanisms of Actions and Effects on Epithelial Ovarian Cancers. IJMS. 2022;23:10078. https:\/\/doi.org\/10.3390\/ijms231710078.","journal-title":"IJMS"},{"key":"2813_CR6","doi-asserted-by":"publisher","first-page":"730765.","DOI":"10.3389\/fimmu.2021.730765","volume":"12","author":"R El Baba","year":"2021","unstructured":"El Baba R, Herbein G. Immune Landscape of CMV Infection in Cancer Patients: From \u201cCanonical\u201d Diseases Toward Virus-Elicited Oncomodulation. Front Immunol. 2021;12:730765. https:\/\/doi.org\/10.3389\/fimmu.2021.730765.","journal-title":"Front Immunol"},{"key":"2813_CR7","doi-asserted-by":"publisher","first-page":"130.","DOI":"10.3389\/fcimb.2020.00130","volume":"10","author":"E Forte","year":"2020","unstructured":"Forte E, Zhang Z, Thorp EB, Hummel M. Cytomegalovirus Latency and Reactivation: An Intricate Interplay With the Host Immune Response. Front Cell Infect Microbiol. 2020;10:130. https:\/\/doi.org\/10.3389\/fcimb.2020.00130.","journal-title":"Front Cell Infect Microbiol"},{"key":"2813_CR8","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3390\/v10080408","volume":"10","author":"G Herbein","year":"2018","unstructured":"Herbein G. The Human Cytomegalovirus, from Oncomodulation to Oncogenesis. Viruses. 2018;10:408. https:\/\/doi.org\/10.3390\/v10080408.","journal-title":"Viruses"},{"key":"2813_CR9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.femsre.2003.07.005","volume":"28","author":"J Cinatl","year":"2004","unstructured":"Cinatl J, Vogel J-U, Kotchetkov R, Wilhelm Doerr H. Oncomodulatory signals by regulatory proteins encoded by human cytomegalovirus: a novel role for viral infection in tumor progression. FEMS Microbiol Rev. 2004;28:59\u201377. https:\/\/doi.org\/10.1016\/j.femsre.2003.07.005.","journal-title":"FEMS Microbiol Rev"},{"key":"2813_CR10","doi-asserted-by":"publisher","first-page":"2462.","DOI":"10.3390\/v14112462","volume":"14","author":"G Herbein","year":"2022","unstructured":"Herbein G. High-Risk Oncogenic Human Cytomegalovirus. Viruses. 2022;14:2462. https:\/\/doi.org\/10.3390\/v14112462.","journal-title":"Viruses"},{"key":"2813_CR11","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41388-022-02588-0","volume":"42","author":"X Li","year":"2023","unstructured":"Li X, Zhong Y, Zhang X, Sood AK, Liu J. Spatiotemporal view of malignant histogenesis and macroevolution via formation of polyploid giant cancer cells. Oncogene. 2023;42:665\u201378. https:\/\/doi.org\/10.1038\/s41388-022-02588-0.","journal-title":"Oncogene"},{"key":"2813_CR12","doi-asserted-by":"publisher","first-page":"1017588.","DOI":"10.3389\/fcell.2022.1017588","volume":"10","author":"X Zhou","year":"2022","unstructured":"Zhou X, Zhou M, Zheng M, Tian S, Yang X, Ning Y. et al. Polyploid giant cancer cells and cancer progression. Front Cell Dev Biol. 2022;10:1017588. https:\/\/doi.org\/10.3389\/fcell.2022.1017588.","journal-title":"Front Cell Dev Biol"},{"key":"2813_CR13","doi-asserted-by":"publisher","first-page":"4887","DOI":"10.1038\/onc.2017.72","volume":"36","author":"N Niu","year":"2017","unstructured":"Niu N, Mercado-Uribe I, Liu J. Dedifferentiation into blastomere-like cancer stem cells via formation of polyploid giant cancer cells. Oncogene. 2017;36:4887\u2013900. https:\/\/doi.org\/10.1038\/onc.2017.72.","journal-title":"Oncogene"},{"key":"2813_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2021.10.006","volume":"81","author":"J Liu","year":"2022","unstructured":"Liu J, Erenpreisa J, Sikora E. Polyploid giant cancer cells: An emerging new field of cancer biology. Semin Cancer Biol. 2022;81:1\u20134. https:\/\/doi.org\/10.1016\/j.semcancer.2021.10.006.","journal-title":"Semin Cancer Biol"},{"key":"2813_CR15","doi-asserted-by":"publisher","first-page":"6852.","DOI":"10.3390\/ijms24076852","volume":"24","author":"R Mirzayans","year":"2023","unstructured":"Mirzayans R. The Cellular Response to DNA Damage: From DNA Repair to Polyploidy and Beyond. IJMS. 2023;24:6852. https:\/\/doi.org\/10.3390\/ijms24076852.","journal-title":"IJMS"},{"key":"2813_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09648-4","volume":"22","author":"L Yart","year":"2022","unstructured":"Yart L, Bastida-Ruiz D, Allard M, Dietrich P-Y, Petignat P, Cohen M. Linking unfolded protein response to ovarian cancer cell fusion. BMC Cancer. 2022;22:622. https:\/\/doi.org\/10.1186\/s12885-022-09648-4.","journal-title":"BMC Cancer"},{"key":"2813_CR17","doi-asserted-by":"publisher","first-page":"104056.","DOI":"10.1016\/j.ebiom.2022.104056","volume":"80","author":"Z Nehme","year":"2022","unstructured":"Nehme Z, Pasquereau S, Haidar Ahmad S, El Baba R, Herbein G. Polyploid giant cancer cells, EZH2 and Myc upregulation in mammary epithelial cells infected with high-risk human cytomegalovirus. EBioMedicine. 2022;80:104056. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104056.","journal-title":"EBioMedicine"},{"key":"2813_CR18","doi-asserted-by":"publisher","first-page":"4271.","DOI":"10.3390\/cancers14174271","volume":"14","author":"R El Baba","year":"2022","unstructured":"El Baba R, Pasquereau S, Haidar Ahmad S, Diab-Assaf M, Herbein G. Oncogenic and Stemness Signatures of the High-Risk HCMV Strains in Breast Cancer Progression. Cancers. 2022;14:4271. https:\/\/doi.org\/10.3390\/cancers14174271.","journal-title":"Cancers"},{"key":"2813_CR19","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1038\/s41388-021-01715-7","volume":"40","author":"Z Nehme","year":"2021","unstructured":"Nehme Z, Pasquereau S, Haidar Ahmad S, Coaquette A, Molimard C, Monnien F. et al. Polyploid giant cancer cells, stemness and epithelial-mesenchymal plasticity elicited by human cytomegalovirus. Oncogene. 2021;40:3030\u201346. https:\/\/doi.org\/10.1038\/s41388-021-01715-7.","journal-title":"Oncogene"},{"key":"2813_CR20","doi-asserted-by":"publisher","first-page":"567116.","DOI":"10.3389\/fonc.2020.567116","volume":"10","author":"G Herbein","year":"2020","unstructured":"Herbein G, Nehme Z. Polyploid Giant Cancer Cells, a Hallmark of Oncoviruses and a New Therapeutic Challenge. Front Oncol. 2020;10:567116. https:\/\/doi.org\/10.3389\/fonc.2020.567116.","journal-title":"Front Oncol"},{"key":"2813_CR21","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1111\/cas.13717","volume":"109","author":"K Tanaka","year":"2018","unstructured":"Tanaka K, Goto H, Nishimura Y, Kasahara K, Mizoguchi A, Inagaki M. Tetraploidy in cancer and its possible link to aging. Cancer Sci. 2018;109:2632\u201340. https:\/\/doi.org\/10.1111\/cas.13717.","journal-title":"Cancer Sci"},{"key":"2813_CR22","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.4161\/cc.21722","volume":"11","author":"M Castedo","year":"2012","unstructured":"Castedo M, Senovilla L, Vitale I, Kroemer G. Tetraploid cancer cell precursors in ovarian carcinoma. Cell Cycle. 2012;11:3157\u20138. https:\/\/doi.org\/10.4161\/cc.21722.","journal-title":"Cell Cycle"},{"key":"2813_CR23","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.4161\/cc.21196","volume":"11","author":"L Lv","year":"2012","unstructured":"Lv L, Zhang T, Yi Q, Huang Y, Wang Z, Hou H. et al. Tetraploid cells from cytokinesis failure induce aneuploidy and spontaneous transformation of mouse ovarian surface epithelial cells. Cell Cycle. 2012;11:2864\u201375. https:\/\/doi.org\/10.4161\/cc.21196.","journal-title":"Cell Cycle"},{"key":"2813_CR24","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.ccr.2012.03.044","volume":"21","author":"T Davoli","year":"2012","unstructured":"Davoli T, de Lange T. Telomere-Driven Tetraploidization Occurs in Human Cells Undergoing Crisis and Promotes Transformation of Mouse Cells. Cancer Cell. 2012;21:765\u201376. https:\/\/doi.org\/10.1016\/j.ccr.2012.03.044.","journal-title":"Cancer Cell"},{"key":"2813_CR25","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1158\/1535-7163.MCT-17-0437","volume":"17","author":"BA Jones","year":"2018","unstructured":"Jones BA, Varambally S, Arend RC. Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer. Mol Cancer Ther. 2018;17:591\u2013602. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0437.","journal-title":"Mol Cancer Ther"},{"key":"2813_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-77532-x","volume":"10","author":"K Leitner","year":"2020","unstructured":"Leitner K, Tsibulak I, Wieser V, Knoll K, Reimer D, Marth C. et al. Clinical impact of EZH2 and its antagonist SMARCA4 in ovarian cancer. Sci Rep. 2020;10:20412. https:\/\/doi.org\/10.1038\/s41598-020-77532-x.","journal-title":"Sci Rep"},{"key":"2813_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/903542","volume":"2014","author":"L Zhang","year":"2014","unstructured":"Zhang L, Ding P, Lv H, Zhang D, Liu G, Yang Z. et al. Number of Polyploid Giant Cancer Cells and Expression of EZH2 Are Associated with VM Formation and Tumor Grade in Human Ovarian Tumor. BioMed Res Int. 2014;2014:1\u20139. https:\/\/doi.org\/10.1155\/2014\/903542.","journal-title":"BioMed Res Int"},{"key":"2813_CR28","first-page":"3347","volume":"62","author":"C Cobbs","year":"2002","unstructured":"Cobbs C, Harkins L, Samanta M, Gillespie G, Bharara S, King P, et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 2002;62:3347\u201350.","journal-title":"Cancer Res"},{"key":"2813_CR29","doi-asserted-by":"publisher","first-page":"4333","DOI":"10.18632\/oncotarget.27016","volume":"10","author":"CS Naucl\u00e9r","year":"2019","unstructured":"Naucl\u00e9r CS, Geisler J, Vetvik K. The emerging role of human cytomegalovirus infection in human carcinogenesis: a review of current evidence and potential therapeutic implications. Oncotarget. 2019;10:4333\u201347. https:\/\/doi.org\/10.18632\/oncotarget.27016.","journal-title":"Oncotarget"},{"key":"2813_CR30","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1038\/s41388-023-02709-3","volume":"42","author":"R El Baba","year":"2023","unstructured":"El Baba R, Pasquereau S, Haidar Ahmad S, Monnien F, Abad M, Bibeau F. et al. EZH2-Myc driven glioblastoma elicited by cytomegalovirus infection of human astrocytes. Oncogene. 2023;42:2031\u201345. https:\/\/doi.org\/10.1038\/s41388-023-02709-3.","journal-title":"Oncogene"},{"key":"2813_CR31","doi-asserted-by":"publisher","first-page":"23.","DOI":"10.1186\/s13027-020-00289-5","volume":"15","author":"M Yin","year":"2020","unstructured":"Yin M, Chen A, Zhao F, Ji X, Li C, Wang G. Detection of human cytomegalovirus in patients with epithelial ovarian cancer and its impacts on survival. Infect Agents Cancer. 2020;15:23. https:\/\/doi.org\/10.1186\/s13027-020-00289-5.","journal-title":"Infect Agents Cancer"},{"key":"2813_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-56448-1","volume":"9","author":"E Paradowska","year":"2019","unstructured":"Paradowska E, Jab\u0142o\u0144ska A, Studzi\u0144ska M, Wilczy\u0144ski M, Wilczy\u0144ski JR. Detection and genotyping of CMV and HPV in tumors and fallopian tubes from epithelial ovarian cancer patients. Sci Rep. 2019;9:19935. https:\/\/doi.org\/10.1038\/s41598-019-56448-1.","journal-title":"Sci Rep"},{"key":"2813_CR33","doi-asserted-by":"publisher","first-page":"e9685.","DOI":"10.1097\/MD.0000000000009685","volume":"97","author":"JW Carlson","year":"2018","unstructured":"Carlson JW, R\u00e5destad AF, S\u00f6derberg-Naucler C, Rahbar A. Human cytomegalovirus in high grade serous ovarian cancer possible implications for patients survival. Medicine. 2018;97:e9685. https:\/\/doi.org\/10.1097\/MD.0000000000009685.","journal-title":"Medicine"},{"key":"2813_CR34","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ebiom.2018.03.015","volume":"30","author":"A Kumar","year":"2018","unstructured":"Kumar A, Tripathy MK, Pasquereau S, Al Moussawi F, Abbas W, Coquard L. et al. The Human Cytomegalovirus Strain DB Activates Oncogenic Pathways in Mammary Epithelial Cells. EBioMedicine. 2018;30:167\u201383. https:\/\/doi.org\/10.1016\/j.ebiom.2018.03.015.","journal-title":"EBioMedicine"},{"key":"2813_CR35","doi-asserted-by":"publisher","first-page":"428.","DOI":"10.3390\/cells9020428","volume":"9","author":"J Dud\u00e1s","year":"2020","unstructured":"Dud\u00e1s J, Lad\u00e1nyi A, Ingruber J, Steinbichler TB, Riechelmann H. Epithelial to Mesenchymal Transition: A Mechanism that Fuels Cancer Radio\/Chemoresistance. Cells. 2020;9:428. https:\/\/doi.org\/10.3390\/cells9020428.","journal-title":"Cells"},{"key":"2813_CR36","doi-asserted-by":"publisher","first-page":"696871.","DOI":"10.3389\/fcell.2021.696871","volume":"9","author":"Q Zhao","year":"2021","unstructured":"Zhao Q, Zhang K, Li Z, Zhang H, Fu F, Fu J. et al. High Migration and Invasion Ability of PGCCs and Their Daughter Cells Associated With the Nuclear Localization of S100A10 Modified by SUMOylation. Front Cell Dev Biol. 2021;9:696871. https:\/\/doi.org\/10.3389\/fcell.2021.696871.","journal-title":"Front Cell Dev Biol"},{"key":"2813_CR37","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1093\/biolre\/ioab102","volume":"105","author":"JS Richards","year":"2021","unstructured":"Richards JS, Candelaria NR, Lanz RB. Polyploid giant cancer cells and ovarian cancer: new insights into mitotic regulators and polyploidy. Biol Reprod. 2021;105:305\u201316. https:\/\/doi.org\/10.1093\/biolre\/ioab102.","journal-title":"Biol Reprod"},{"key":"2813_CR38","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/onc.2013.96","volume":"33","author":"S Zhang","year":"2014","unstructured":"Zhang S, Mercado-Uribe I, Xing Z, Sun B, Kuang J, Liu J. Generation of cancer stem-like cells through the formation of polyploid giant cancer cells. Oncogene. 2014;33:116\u201328. https:\/\/doi.org\/10.1038\/onc.2013.96.","journal-title":"Oncogene"},{"key":"2813_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09503-6","volume":"22","author":"RR Bowers","year":"2022","unstructured":"Bowers RR, Andrade MF, Jones CM, White-Gilbertson S, Voelkel-Johnson C, Delaney JR. Autophagy modulating therapeutics inhibit ovarian cancer colony generation by polyploid giant cancer cells (PGCCs). BMC Cancer. 2022;22:410. https:\/\/doi.org\/10.1186\/s12885-022-09503-6.","journal-title":"BMC Cancer"},{"key":"2813_CR40","doi-asserted-by":"publisher","first-page":"5251.","DOI":"10.3390\/cancers13205251","volume":"13","author":"N Iwahashi","year":"2021","unstructured":"Iwahashi N, Ikezaki M, Fujimoto M, Komohara Y, Fujiwara Y, Yamamoto M. et al. Lipid Droplet Accumulation Independently Predicts Poor Clinical Prognosis in High-Grade Serous Ovarian Carcinoma. Cancers. 2021;13:5251. https:\/\/doi.org\/10.3390\/cancers13205251.","journal-title":"Cancers"},{"key":"2813_CR41","doi-asserted-by":"publisher","first-page":"112011.","DOI":"10.1016\/j.yexcr.2020.112011","volume":"392","author":"M Yoshihara","year":"2020","unstructured":"Yoshihara M, Yamakita Y, Kajiyama H, Senga T, Koya Y, Yamashita M. et al. Filopodia play an important role in the trans-mesothelial migration of ovarian cancer cells. Exp Cell Res. 2020;392:112011. https:\/\/doi.org\/10.1016\/j.yexcr.2020.112011.","journal-title":"Exp Cell Res"},{"key":"2813_CR42","doi-asserted-by":"publisher","first-page":"e80120.","DOI":"10.1371\/journal.pone.0080120","volume":"8","author":"S Zhang","year":"2013","unstructured":"Zhang S, Mercado-Uribe I, Hanash S, Liu J. iTRAQ-Based Proteomic Analysis of Polyploid Giant Cancer Cells and Budding Progeny Cells Reveals Several Distinct Pathways for Ovarian Cancer Development. PLoS ONE. 2013;8:e80120. https:\/\/doi.org\/10.1371\/journal.pone.0080120.","journal-title":"PLoS ONE"},{"key":"2813_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-576","volume":"14","author":"H Lv","year":"2014","unstructured":"Lv H, Shi Y, Zhang L, Zhang D, Liu G, Yang Z. et al. Polyploid giant cancer cells with budding and the expression of cyclin E, S-phase kinase-associated protein 2, stathmin associated with the grading and metastasis in serous ovarian tumor. BMC Cancer. 2014;14:576. https:\/\/doi.org\/10.1186\/1471-2407-14-576.","journal-title":"BMC Cancer"},{"key":"2813_CR44","doi-asserted-by":"publisher","first-page":"33.","DOI":"10.3389\/fonc.2012.00033","volume":"2","author":"B Davidson","year":"2012","unstructured":"Davidson B, Trop\u00e9 CG, Reich R. Epithelial\u2013Mesenchymal Transition in Ovarian Carcinoma. Front Oncol. 2012;2:33. https:\/\/doi.org\/10.3389\/fonc.2012.00033.","journal-title":"Front Oncol"},{"key":"2813_CR45","doi-asserted-by":"publisher","first-page":"178.","DOI":"10.3390\/cancers10060178","volume":"10","author":"R Aloni-Grinstein","year":"2018","unstructured":"Aloni-Grinstein R, Charni-Natan M, Solomon H, Rotter V. p53 and the Viral Connection: Back into the Future \u2021. Cancers. 2018;10:178. https:\/\/doi.org\/10.3390\/cancers10060178.","journal-title":"Cancers"},{"key":"2813_CR46","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.cell.2010.01.031","volume":"141","author":"T Davoli","year":"2010","unstructured":"Davoli T, Denchi EL, De Lange T. Persistent Telomere Damage Induces Bypass of Mitosis and Tetraploidy. Cell. 2010;141:81\u201393. https:\/\/doi.org\/10.1016\/j.cell.2010.01.031.","journal-title":"Cell"},{"key":"2813_CR47","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1158\/0008-5472.CAN-03-3380","volume":"64","author":"J Liu","year":"2004","unstructured":"Liu J, Yang G, Thompson-Lanza JA, Glassman A, Hayes K, Patterson A. et al. A Genetically Defined Model for Human Ovarian Cancer. Cancer Res. 2004;64:1655\u201363. https:\/\/doi.org\/10.1158\/0008-5472.CAN-03-3380.","journal-title":"Cancer Res"},{"key":"2813_CR48","doi-asserted-by":"publisher","first-page":"135.","DOI":"10.4103\/ijpvm.IJPVM_75_19","volume":"11","author":"G Yadav","year":"2020","unstructured":"Yadav G, Vashisht M, Yadav V, Shyam R. Molecular biomarkers for early detection and prevention of ovarian cancer\u2014A gateway for good prognosis: A narrative review. Int J Prev Med. 2020;11:135. https:\/\/doi.org\/10.4103\/ijpvm.IJPVM_75_19.","journal-title":"Int J Prev Med"},{"key":"2813_CR49","doi-asserted-by":"publisher","first-page":"4202","DOI":"10.1182\/blood-2008-03-147645","volume":"112","author":"S Sander","year":"2008","unstructured":"Sander S, Bullinger L, Klapproth K, Fiedler K, Kestler HA, Barth TFE. et al. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood. 2008;112:4202\u201312. https:\/\/doi.org\/10.1182\/blood-2008-03-147645.","journal-title":"Blood"},{"key":"2813_CR50","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1002\/ijc.33727","volume":"149","author":"AY Coughlan","year":"2021","unstructured":"Coughlan AY, Testa G. Exploiting epigenetic dependencies in ovarian cancer therapy. Int J Cancer. 2021;149:1732\u201343. https:\/\/doi.org\/10.1002\/ijc.33727.","journal-title":"Int J Cancer"},{"key":"2813_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08413-3","volume":"21","author":"BM Reid","year":"2021","unstructured":"Reid BM, Vyas S, Chen Z, Chen A, Kanetsky PA, Permuth JB. et al. Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma. BMC Cancer. 2021;21:714. https:\/\/doi.org\/10.1186\/s12885-021-08413-3.","journal-title":"BMC Cancer"},{"key":"2813_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01786-y","volume":"22","author":"J Chen","year":"2023","unstructured":"Chen J, Hong JH, Huang Y, Liu S, Yin J, Deng P. et al. EZH2 mediated metabolic rewiring promotes tumor growth independently of histone methyltransferase activity in ovarian cancer. Mol Cancer. 2023;22:85. https:\/\/doi.org\/10.1186\/s12943-023-01786-y.","journal-title":"Mol Cancer"},{"key":"2813_CR53","doi-asserted-by":"publisher","first-page":"1760675.","DOI":"10.1080\/23723556.2020.1760675","volume":"7","author":"S Karakashev","year":"2020","unstructured":"Karakashev S, Zhang R. Targeting CARM1 in ovarian cancer with EZH2 and PARP inhibitors. Mol Cell Oncol. 2020;7:1760675. https:\/\/doi.org\/10.1080\/23723556.2020.1760675.","journal-title":"Mol Cell Oncol"},{"key":"2813_CR54","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41568-022-00503-z","volume":"22","author":"LE Kandalaft","year":"2022","unstructured":"Kandalaft LE, Dangaj Laniti D, Coukos G. Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation. Nat Rev Cancer. 2022;22:640\u201356. https:\/\/doi.org\/10.1038\/s41568-022-00503-z.","journal-title":"Nat Rev Cancer"},{"key":"2813_CR55","doi-asserted-by":"publisher","first-page":"601512.","DOI":"10.3389\/fonc.2021.601512","volume":"11","author":"JM Reyes-Gonz\u00e1lez","year":"2021","unstructured":"Reyes-Gonz\u00e1lez JM, Vivas-Mej\u00eda PE. c-MYC and Epithelial Ovarian Cancer. Front Oncol. 2021;11:601512. https:\/\/doi.org\/10.3389\/fonc.2021.601512.","journal-title":"Front Oncol"},{"key":"2813_CR56","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrc2644","volume":"9","author":"RC Bast","year":"2009","unstructured":"Bast RC, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009;9:415\u201328. https:\/\/doi.org\/10.1038\/nrc2644.","journal-title":"Nat Rev Cancer"},{"key":"2813_CR57","first-page":"93","volume":"4","author":"M Shichiri","year":"1993","unstructured":"Shichiri M, Hanson K, Sedivy J. Effects of c-myc expression on proliferation, quiescence, and the G0 to G1 transition in nontransformed cells. Cell Growth Differ. 1993;4:93\u2013104.","journal-title":"Cell Growth Differ"},{"key":"2813_CR58","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41418-021-00878-w","volume":"29","author":"T Velletri","year":"2022","unstructured":"Velletri T, Villa CE, Cilli D, Barzaghi B, Lo Riso P, Lupia M. et al. Single cell-derived spheroids capture the self-renewing subpopulations of metastatic ovarian cancer. Cell Death Differ. 2022;29:614\u201326. https:\/\/doi.org\/10.1038\/s41418-021-00878-w.","journal-title":"Cell Death Differ"},{"key":"2813_CR59","doi-asserted-by":"publisher","first-page":"e84941.","DOI":"10.1371\/journal.pone.0084941","volume":"9","author":"J Liao","year":"2014","unstructured":"Liao J, Qian F, Tchabo N, Mhawech-Fauceglia P, Beck A, Qian Z. et al. Ovarian Cancer Spheroid Cells with Stem Cell-Like Properties Contribute to Tumor Generation, Metastasis and Chemotherapy Resistance through Hypoxia-Resistant Metabolism. PLoS ONE. 2014;9:e84941. https:\/\/doi.org\/10.1371\/journal.pone.0084941.","journal-title":"PLoS ONE"},{"key":"2813_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s13008-022-00079-y","volume":"17","author":"TG Shepherd","year":"2022","unstructured":"Shepherd TG, Dick FA. Principles of dormancy evident in high-grade serous ovarian cancer. Cell Div. 2022;17:2. https:\/\/doi.org\/10.1186\/s13008-022-00079-y.","journal-title":"Cell Div"},{"key":"2813_CR61","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1242\/bio.2012653","volume":"1","author":"JC Pease","year":"2012","unstructured":"Pease JC, Brewer M, Tirnauer JS. Spontaneous spheroid budding from monolayers: a potential contribution to ovarian cancer dissemination. Biol Open. 2012;1:622\u20138. https:\/\/doi.org\/10.1242\/bio.2012653.","journal-title":"Biol Open"},{"key":"2813_CR62","doi-asserted-by":"publisher","first-page":"262.","DOI":"10.3390\/cancers13020262","volume":"13","author":"M Robinson","year":"2021","unstructured":"Robinson M, Gilbert SF, Waters JA, Lujano-Olazaba O, Lara J, Alexander LJ. et al. Characterization of SOX2, OCT4 and NANOG in Ovarian Cancer Tumor-Initiating Cells. Cancers. 2021;13:262. https:\/\/doi.org\/10.3390\/cancers13020262.","journal-title":"Cancers"},{"key":"2813_CR63","doi-asserted-by":"publisher","first-page":"589601.","DOI":"10.3389\/fonc.2020.589601","volume":"10","author":"A Martincuks","year":"2020","unstructured":"Martincuks A, Li P-C, Zhao Q, Zhang C, Li Y-J, Yu H. et al. CD44 in Ovarian Cancer Progression and Therapy Resistance\u2014A Critical Role for STAT3. Front Oncol. 2020;10:589601. https:\/\/doi.org\/10.3389\/fonc.2020.589601.","journal-title":"Front Oncol"},{"key":"2813_CR64","doi-asserted-by":"publisher","first-page":"9313","DOI":"10.18632\/oncotarget.3220","volume":"6","author":"Y Gao","year":"2015","unstructured":"Gao Y, Foster R, Yang X, Feng Y, Shen JK, Mankin HJ. et al. Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer. Oncotarget. 2015;6:9313\u201326. https:\/\/doi.org\/10.18632\/oncotarget.3220.","journal-title":"Oncotarget"},{"key":"2813_CR65","doi-asserted-by":"publisher","first-page":"802.","DOI":"10.3389\/fonc.2019.00802","volume":"9","author":"J Zhou","year":"2019","unstructured":"Zhou J, Du Y, Lu Y, Luan B, Xu C, Yu Y. et al. CD44 Expression Predicts Prognosis of Ovarian Cancer Patients Through Promoting Epithelial-Mesenchymal Transition (EMT) by Regulating Snail, ZEB1, and Caveolin-1. Front Oncol. 2019;9:802. https:\/\/doi.org\/10.3389\/fonc.2019.00802.","journal-title":"Front Oncol"},{"key":"2813_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-017-0638-3","volume":"16","author":"M Lupia","year":"2017","unstructured":"Lupia M, Cavallaro U. Ovarian cancer stem cells: still an elusive entity?. Mol Cancer. 2017;16:64. https:\/\/doi.org\/10.1186\/s12943-017-0638-3.","journal-title":"Mol Cancer"},{"key":"2813_CR67","doi-asserted-by":"publisher","first-page":"838.","DOI":"10.3390\/cancers11060838","volume":"11","author":"N Loret","year":"2019","unstructured":"Loret N, Denys H, Tummers P, Berx G. The Role of Epithelial-to-Mesenchymal Plasticity in Ovarian Cancer Progression and Therapy Resistance. Cancers. 2019;11:838. https:\/\/doi.org\/10.3390\/cancers11060838.","journal-title":"Cancers"},{"key":"2813_CR68","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.4161\/cc.20308","volume":"11","author":"F Ricci","year":"2012","unstructured":"Ricci F, Bernasconi S, Perego P, Ganzinelli M, Russo G, Bono F. et al. Ovarian carcinoma tumor-initiating cells have a mesenchymal phenotype. Cell Cycle. 2012;11:1966\u201376. https:\/\/doi.org\/10.4161\/cc.20308.","journal-title":"Cell Cycle"},{"key":"2813_CR69","doi-asserted-by":"publisher","first-page":"684.","DOI":"10.3390\/cancers15030684","volume":"15","author":"R Tedja","year":"2023","unstructured":"Tedja R, Alvero AB, Fox A, Cardenas C, Pitruzzello M, Chehade H. et al. Generation of Stable Epithelial\u2013Mesenchymal Hybrid Cancer Cells with Tumorigenic Potential. Cancers. 2023;15:684. https:\/\/doi.org\/10.3390\/cancers15030684.","journal-title":"Cancers"},{"key":"2813_CR70","doi-asserted-by":"publisher","first-page":"623.","DOI":"10.3390\/cells9030623","volume":"9","author":"T-T Liao","year":"2020","unstructured":"Liao T-T, Yang M-H. Hybrid Epithelial\/Mesenchymal State in Cancer Metastasis: Clinical Significance and Regulatory Mechanisms. Cells. 2020;9:623. https:\/\/doi.org\/10.3390\/cells9030623.","journal-title":"Cells"},{"key":"2813_CR71","doi-asserted-by":"publisher","first-page":"561.","DOI":"10.3390\/cancers12030561","volume":"12","author":"S Pathak","year":"2020","unstructured":"Pathak S, Wilczy\u0144ski JR, Paradowska E. Factors in Oncogenesis: Viral Infections in Ovarian Cancer. Cancers. 2020;12:561. https:\/\/doi.org\/10.3390\/cancers12030561.","journal-title":"Cancers"},{"key":"2813_CR72","doi-asserted-by":"publisher","first-page":"4031","DOI":"10.1158\/1078-0432.CCR-20-0369","volume":"26","author":"G Stragliotto","year":"2020","unstructured":"Stragliotto G, Pantalone MR, Rahbar A, Bartek J, S\u00f6derberg-Naucler C. Valganciclovir as Add-on to Standard Therapy in Glioblastoma Patients. Clin Cancer Res. 2020;26:4031\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0369.","journal-title":"Clin Cancer Res"},{"key":"2813_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-018-0074-4","volume":"3","author":"CS Nelson","year":"2018","unstructured":"Nelson CS, Herold BC, Permar SR. A new era in cytomegalovirus vaccinology: considerations for rational design of next-generation vaccines to prevent congenital cytomegalovirus infection. Npj Vaccines. 2018;3:38. https:\/\/doi.org\/10.1038\/s41541-018-0074-4.","journal-title":"Npj Vaccines"},{"key":"2813_CR74","doi-asserted-by":"publisher","first-page":"1202138.","DOI":"10.3389\/fcimb.2023.1202138","volume":"13","author":"C Yu","year":"2023","unstructured":"Yu C, He S, Zhu W, Ru P, Ge X, Govindasamy K. Human cytomegalovirus in cancer: the mechanism of HCMV-induced carcinogenesis and its therapeutic potential. Front Cell Infect Microbiol. 2023;13:1202138. https:\/\/doi.org\/10.3389\/fcimb.2023.1202138.","journal-title":"Front Cell Infect Microbiol"},{"key":"2813_CR75","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/nrneurol.2017.64","volume":"13","author":"M Weller","year":"2017","unstructured":"Weller M, Roth P, Preusser M, Wick W, Reardon DA, Platten M. et al. Vaccine-based immunotherapeutic approaches to gliomas and beyond. Nat Rev Neurol. 2017;13:363\u201374. https:\/\/doi.org\/10.1038\/nrneurol.2017.64.","journal-title":"Nat Rev Neurol"},{"key":"2813_CR76","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.4161\/cc.25163","volume":"12","author":"M Amatangelo","year":"2013","unstructured":"Amatangelo M, Garipov A, Li H, Conejo-Garcia JR, Speicher D, Zhang R. Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition. Cell Cycle. 2013;12:2113\u20139. https:\/\/doi.org\/10.4161\/cc.25163.","journal-title":"Cell Cycle"},{"key":"2813_CR77","doi-asserted-by":"publisher","first-page":"98348","DOI":"10.18632\/oncotarget.21311","volume":"8","author":"T Yu","year":"2017","unstructured":"Yu T, Wang Y, Hu Q, Wu W, Wu Y, Wei W. et al. The EZH2 inhibitor GSK343 suppresses cancer stem-like phenotypes and reverses mesenchymal transition in glioma cells. Oncotarget. 2017;8:98348\u201359. https:\/\/doi.org\/10.18632\/oncotarget.21311.","journal-title":"Oncotarget"},{"key":"2813_CR78","doi-asserted-by":"publisher","first-page":"e1004136.","DOI":"10.1371\/journal.ppat.1004136","volume":"10","author":"G Sourvinos","year":"2014","unstructured":"Sourvinos G, Morou A, Sanidas I, Codruta I, Ezell SA, Doxaki C. et al. The Downregulation of GFI1 by the EZH2-NDY1\/KDM2B-JARID2 Axis and by Human Cytomegalovirus (HCMV) Associated Factors Allows the Activation of the HCMV Major IE Promoter and the Transition to Productive Infection. PLoS Pathog. 2014;10:e1004136. https:\/\/doi.org\/10.1371\/journal.ppat.1004136.","journal-title":"PLoS Pathog"},{"key":"2813_CR79","doi-asserted-by":"publisher","first-page":"772160.","DOI":"10.3389\/fimmu.2021.772160","volume":"12","author":"S Haidar Ahmad","year":"2021","unstructured":"Haidar Ahmad S, Pasquereau S, El Baba R, Nehme Z, Lewandowski C, Herbein G. Distinct Oncogenic Transcriptomes in Human Mammary Epithelial Cells Infected With Cytomegalovirus. Front Immunol. 2021;12:772160. https:\/\/doi.org\/10.3389\/fimmu.2021.772160.","journal-title":"Front Immunol"},{"key":"2813_CR80","doi-asserted-by":"publisher","unstructured":"Bilandzic M, Stenvers KL. Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time. JoVE. 2014;51655. https:\/\/doi.org\/10.3791\/51655.","DOI":"10.3791\/51655"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-023-02813-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-023-02813-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-023-02813-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T23:15:54Z","timestamp":1696547754000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-023-02813-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,26]]},"references-count":80,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2023,10,6]]}},"alternative-id":["2813"],"URL":"https:\/\/doi.org\/10.1038\/s41388-023-02813-4","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,26]]},"assertion":[{"value":"10 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki. A written informed consent for participation was obtained from all patients. The study was authorized by the local ethics committees of Besan\u00e7on University Hospital (Besan\u00e7on, France) and the French Research Ministry (AC-2015-2496, CNIL n\u00b01173545, NF-S-138 96900 n\u00b0F2015).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}}]}}